Royal Bank of Canada
SLN

Royal Bank of Canada’s Silence Therapeutics SLN Stock Holding History

Royal Bank of Canada’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$0 Hold
16
– – ﹤0.01% 7639
2025
Q4 		$0 Sell
16
-1,120
-99% -$7.17K ﹤0.01% 7592
2025
Q3 		$6K Sell
1,136
-1,326
-54% -$7.37K ﹤0.01% 6665
2025
Q2 		$14K Sell
2,462
-1,801
-42% -$7.72K ﹤0.01% 6386
2025
Q1 		$12K Buy
4,263
+2,748
+181% +$13.4K ﹤0.01% 6106
2024
Q4 		$10K Sell
1,515
-426
-22% -$5.5K ﹤0.01% 6353
2024
Q3 		$35K Sell
1,941
-2,775
-59% -$51.6K ﹤0.01% 5856
2024
Q2 		$89K Buy
+4,716
New +$100K ﹤0.01% 5337

Other funds holding SLN

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

Royal Bank of Canada's SLN Position: Q1 2026 in Review

Royal Bank of Canada held its Silence Therapeutics (SLN) position steady in Q1 2026 at 16 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #7639.

Royal Bank of Canada first reported a position in SLN in Q2 2024 and has held it in 8 quarters since. The position peaked at $89K in Q2 2024. 56 funds tracked by Wall St. Rank hold SLN as of Q1 2026.

  • Royal Bank of Canada held 16 shares of Silence Therapeutics worth $0 as of Q1 2026.
  • Royal Bank of Canada left its Silence Therapeutics share count unchanged in Q1 2026.
  • Silence Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #7639 holding.
  • Royal Bank of Canada first reported a position in Silence Therapeutics in Q2 2024 and has held it in 8 quarters since.
  • Royal Bank of Canada's Silence Therapeutics position peaked at $89K in Q2 2024.
  • 56 funds tracked by Wall St. Rank held Silence Therapeutics as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.